Chinese maker of 3D-printed drugs secures $15m in funding
Startup Triastek has already filed patent applications in Japan and the US
Triastek develops 3D-printed medicines and their production facilities. (Photo courtesy of Triastek)
BEIJING -- Triastek, a Chinese startup using 3D technology to develop medicines, has raised about 100 million yuan ($15 million) in a Series A+ funding round.
The lead investor is Dalton Venture, while the co-investors are Shanghai Tofflon Science and Technology Chairman Zheng Xiaodong and Yunqi Partners.
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapterFind out more
Free access for everyone - Sep. 30